Dr. Ronald E. Cape to Retire from EntreMed Board of... (nts of the NIH National Library of Medic...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Dr. Ronald E. Cape to Retire from EntreMed Board of Directors

Date:4/7/2008

nts of the NIH National Library of Medicine.

In announcing his pending retirement, Dr. Cape commented, "I am pleased to have served on the EntreMed Board during its rebuilding period. The Company has promising programs that are making good progress, but I would now like to spend more time with my family and friends. I wish everyone at EntreMed continued progress."

EntreMed Board Chairman, Michael M. Tarnow commented, "Dr. Cape has been a distinguished member of our Board since he joined in 2003. He has been involved in the biotech industry virtually from the beginning, and he has participated actively in its development since those early days. His valuable contributions to the field of biotechnology and his contribution to EntreMed are hallmarks of his leadership and commitment to the industry. We are honored to have had the opportunity to draw from Dr. Cape's vast knowledge and sage advice. While his service will be missed, we wish him all the best in his retirement."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in var
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. International Soccer Superstar Ronaldinho Signs With Nutrilite(TM)
2. MCM Completes Westwood Replacement Hospital - Ronald Reagan UCLA Medical Center
3. Philadelphia Ronald McDonald House(R) at Front & Erie Celebrates Grand Opening
4. Mayo Clinics Dr. Ronald C. Petersen Awarded Leon Thal Prize for Excellence in Dementia Research
5. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
6. St. Christophers Foundation For Children Ronald McDonald(R) Care Mobile Making Tri-State Visits to Provide Dental Care to Children at No Cost
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. East Ridge Retirement Village Announces Enhancement Plan
9. Increased Heart Risk Seen for Retired NFL Players
10. Mayo Clinic finds retired NFL players at increased risk for heart problems
11. AARP Deeply Disappointed by Supreme Court Decision on Retiree Health Care Benefits

Post Your Comments:

(Date:12/14/2009)... Dec. 14 Tough Enough To Wear Pink(TM) ... cancer, celebrated its fifth anniversary at the signature ... Wrangler National Finals Rodeo (Wrangler NFR) in Las ... rough-and-tumble rodeo cowboys, the support of the western ... sold-out crowd sported pink shirts, hats, bracelets and ...

(Date:12/14/2009)... higher than generally thought, raising concerns about increased risk for cancer, ... San Francisco (UCSF) imaging specialists. , ... San ... CT procedures vary widely and are higher than generally thought, raising ... led by University of California, San Francisco (UCSF) imaging ...

(Date:12/14/2009)... Federation of America (HFA) expresses its concern regarding ... 929 and the American Red Cross of Pennsylvania ... skilled workers to provide clean, safe blood to ... as clotting factor for use in treating hemophilia ... of Blood Services at the American Red Cross ...

(Date:12/14/2009)... the bump in odds is small and shouldn,t worry ... News) -- Older women who take antidepressants may have ... and death compared to women not on the medications, ... be different from clinical significance," stressed Dr. Jordan W. ... School, and lead author of a report in the ...

(Date:12/14/2009)... might lead to better treatments for asthma, COPD, researchers ... have identified five genetic variants that influence lung function, ... for lung diseases. , The international team of researchers ... the 2.5 million sites across the human genome in ... the team to the five common genetic variants associated ...

Breaking Medicine News(10 mins):Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3 Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4 Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5 Health News:HFA Voices Blood Safety Concerns 2 Health News:Antidepressants May Raise Women's Stroke Risk 2 Health News:Antidepressants May Raise Women's Stroke Risk 3

[0] Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary [0] Variable Doses of Radiation Raise Safety Concerns for CT Procedures [0] HFA Voices Blood Safety Concerns [0] Antidepressants May Raise Women's Stroke Risk [0] Five Gene Variants May Be Linked to Lung Disease

... DRAXIS Health Inc, (TSX:,DAX) (NASDAQ: DRAX ) has applied ... Issuer Bid (NCIB), subject to TSX approval, to buy back ... maximum number of common shares which may be purchased for,cancellation ... which,represents 10% of the common shares in the public float ...

... G. Komen for the Cure, Participates in Nationwide Campaign Challenging U.S. to ... ... Jan. 11, elected officials,will join advocates from the San Francisco Bay Area ... pink, highlighting the urgent need,to address disparities in breast cancer early detection ...

... Alarming New HIV Rates; Governor Should Cut,Bureaucracy, Corporate ... Healthcare,Foundation (AHF) today urged California Governor Arnold Schwarzenegger ... cuts in AIDS services,that will reduce and threaten ... HIV/AIDS as he seeks to close a $14 ...

... 10 The U.K. is currently dealing,with an outbreak ... infect,hundreds of thousands of people in the coming weeks. ... the U.K.,s Health Protection Agency,(HPA), says doctors and hospitals ... People suffering from the virus are being asked to ...

... blood cell numbers , A common treatment ... (rbcs) caused by their insufficient production, excessive destruction, or ... a hormone that stimulates the production of rbc precursors ... do not respond to treatment with Epo. However, a ...

... study shows preconditioning cardiac cells helps organ better tolerate loss ... Just as daily runs can prepare you to survive a ... could condition cardiac cells to better withstand the damage of ... of Cincinnati suggests. , Ultimately, if validated in humans, these ...

DRAXIS Announces Application for Normal Course Issuer Bid San Francisco City Hall Turns Pink, Draws Attention to Disparities in Breast Cancer Screening, Treatment AHF to Schwarzenegger: 'AIDS Cuts Are Deadly'CeraLyte ORS to Prevent Dehydration from Norovirus Outbreak JCI online early table of contents: Jan. 10 2008 Priming Heart Before an Attack Could Limit Damage

(Date:12/14/2009)... we have been tracking Tianyin Pharmaceuticals (NYSE Amex: ... up had been with the potential dilution from "in-the-money" ... guidance of $11.3 million represents a 43.0% increase from ... the increase in shares poses some uncertainty regarding the ... share price and the Treasury method of accounting for ...

(Date:12/14/2009)... -- According to Millennium Research Group (MRG), the ... use of safety devices for small-bore connectors for ... driver of the enteral feeding device markets in ... US and European Markets for Enteral Feeding Devices ... segment will experience the greatest impact from facilities ...

(Date:12/14/2009)... Manchester Pharmaceuticals, Inc.(TM) announced today the ... On October 22, 2009, the US Food and ... for patients suffering from gallstones in whom surgery ... or advanced age. ,, Chenodal prescriptions have started ... Health Resources ("Centric"), a specialty pharmacy company. ...

Breaking Medicine Technology:GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2 Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2 Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3 Manchester Announces Availability of Chenodal(TM) 2 GenVaults GenSolve 28TM 29 Reagents Enable State of the Art Genomic Analysis of Dried Blood Spots 53720 1 GenVaults GenSolve 28TM 29 Reagents Enable State of the Art Genomic Analysis of Dried Blood Spots 53720 2 GenVaults GenSolve 28TM 29 Reagents Enable State of the Art Genomic Analysis of Dried Blood Spots 53720 3 Effient 28TM 29 is Now Available in Pharmacies 53716 1 Effient 28TM 29 is Now Available in Pharmacies 53716 2 Effient 28TM 29 is Now Available in Pharmacies 53716 3 Effient 28TM 29 is Now Available in Pharmacies 53716 4 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 1 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 2 BioNeutrals Ygiene 28TM 29 Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 13384 3

[0] GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms [0] Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 [0] Manchester Announces Availability of Chenodal(TM)

... the majority of acute lymphoblastic leukemia relapse cases arise from ... , MEMPHIS, Tenn., Nov. 27 ... distinctive genetic changes in the cancer cells of children with ... a pathway to designing treatments for ALL relapse in children ...

... and University of Louisville hand surgeons performed ... resident, Jan "Erik" Hondusky, at Louisville,s Jewish Hospital Hand ... procedure began around noon and was completed shortly after ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20081125/DC48555-a ...

Other Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2 St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3 Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2 Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3

St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center

... preparation an important step ... Scrub Care brand Prevail-Fx Prevail ... efficacy and safety for your ... the highest level of infection ...

... Titer Performance Panel consists of plasma specimens ... positive for antibodies to the Hepatitis C ... by manufacturers and diagnostic laboratories to evaluate ... major test systems are included for comparative ...

... BioSynthetic Mesh is a ... in the central section ... film of porcine collagen. ... the Avaulta™ BioSynthetic Mesh ...

FasLata® Allograft Tissue delivers the durability of natural tissue with all the corresponding benefits of ingrowth and natural adaptation to surrounding tissues....

Medicine Products:

Scrub Care® Brand Prevail-Fx®Anti-HCV Low Titer Performance Panel Avaulta™ Anterior BioSynthetic Support System FasLata® Allograft Tissue

Dr. Ronald E. Cape to Retire from EntreMed Board of...(nts of the NIH National Library of Medic...),Health